other material
confidence high
sentiment positive
materiality 0.75
Compass reports CTX-009 42% ORR in biliary tract cancers; to start U.S. Phase 2 in Q3 2022
Compass Therapeutics, Inc.
- CTX-009 + paclitaxel achieved 42% ORR (10 PRs) out of 24 patients with advanced biliary tract cancers.
- Clinical benefit rate 92% (22/24 patients had PR or stable disease); responses across all four BTC subtypes.
- Safety consistent with Phase 1: common AEs included hypertension (50%) and neutropenia (54.2%); manageable.
- Plans to initiate Stage 2 of Phase 2 study in the U.S. in Q3 2022, following Simon Two-Stage design criteria met.